Remacemide

From Self-sufficiency
Revision as of 16:46, 30 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): hallucinogen-stub)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Remacemide
150px
Systematic (IUPAC) name
N-(1-methyl-1,2-diphenylethyl)glycinamide
Identifiers
CAS Number 128298-28-2
ATC code none
PubChem CID 60511
Synonyms 2-amino-N-[1,2-di(phenyl)propan-2-yl]acetamide
Chemical data
Formula C17H20N2O
Molar mass 268.3535 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Remacemide is a drug which acts as a low-affinity NMDA antagonist with sodium channel blocking properties.[1] It has been studied for the treatment of acute ischemic stroke[2] and epilepsy[3].

References

  1. Wright, LK; Pearson, EC; Hammond, TG; Paule, MG (2007 May-Jun). "Behavioral effects associated with chronic ketamine or remacemide exposure in rats". Neurotoxicol Teratol. 29 (3): 348–59. doi:10.1016/j.ntt.2006.12.004. PMID 17291718.  Check date values in: |date= (help)
  2. Dyker, AG; Lees, KR (1999). "Remacemide Hydrochloride: A Double-Blind, Placebo-Controlled, Safety and Tolerability Study in Patients With Acute Ischemic Stroke". Stroke. 30 (9): 1796–1801. PMID 10471426. 
  3. Wesnes, KA; Edgar, C; Dean, AD; Wroe, SJ (2009). "The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy". Epilepsy & behavior : E&B. 14 (3): 522–8. doi:10.1016/j.yebeh.2008.11.012. PMID 19111629.